Secondary Use of the EHR via Pseudonymisation

Klaus Pommerening, Mainz Michael Reng, Regensburg

TMF = Telematikplattform für die medizinischen Forschungsnetze [Telematics Platform for the German Health Research Networks]



Contents

- 1. EHR and Pseudonyms
- 2. 5 Scenarios for Secondary Use
- 3. Results
- 4. Discussion



Uses of the EHR

- Primary use: Treatment context.
- Secondary uses:
 - Disease specific clinical or epidemiological research projects,
 - Health care research, assessment of treatment quality, health economy.

Typical aspects of secondary uses:

- Outside of treatment context and professional discretion (of the treating physician),
- The identity of the patient doesn't matter.



For secondary use of the EHR:

- Protect the identities of the patients.
- Anonymisation whereever possible.
 Drawbacks of anonymisation:
 - No association between data from distinct sources
 - ... or from distinct points of time.
 - No way back to the patient for feedback
 - ... or for recruiting suitable patients for a new research project.



Pseudonyms

- The golden mean between anonymous data and identity (or identity revealing) data.
- Almost as good as anonymity, depending on context –
 - one-way pseudonyms can't be reversed,
 - reversible pseudonyms allow re-identification of the individual.
 - Written informed consent necessary for reversibility!




Basic Types of Pseudonyms

- Untraceable pseudonyms (Chaum ca 1980)
 - Based on blind digital signature,
 - Under control of owner,
 - Not suited for secondary uses of the EHR.
- TTP-generated pseudonyms
 - Trusted Third Party = »Vertrauensstelle« or »Datentreuhänder« (e. g. a notary).
 - Example: Cancer registry (Michaelis/Pomm. 1993).



TTP-generated Pseudonyms (Basic Model)





Contents

- 1. EHR and Pseudonyms
- 2. 5 Scenarios for Secondary Use
- 3. Results
- 4. Discussion



(1) Single Data Source, One-Time Secondary Use

- Typical application case for anonymisation.
- Example: A simple statistical evaluation of EHR data.




(2) Overlapping Data Sources, One-Time Secondary Use

- Data from diverse sources must be linked together.
- Examples:
 - Multicentric study,
 - Follow-up data.
- Typical application case for one-way pseudonyms.



Pseudonymisation for One-Time Secondary Use



MDAT = Medical Data IDAT = Identity Data

PID = Unique Patient Identifier

PSN = Pseudonym



Properties of Scenario (2)

- Medical data (MDAT) are encrypted with public key of secondary user –
 - The TTP cannot read the MDAT.
 - Only the secondary user can decrypt them.
- The pseudonym (PSN) is the encrypted PID
 - With a secret key, known only to the TTP,
 - By a one-way procedure.
- The TTP doesn't store anything (except the key).




(3) One-Time Secondary Use with Re-Identification

- Use the »Basic TTP« model,
 - But no reference list, only secret TTP key.
 - PSN service performs reversible encryption procedure.
- Use a non-public (project specific) PID
 - Generated by a separate TTP service.
 - PID service stores association between IDAT and PID (»Patient List«).
- Re-identification involves PSN service and PID service.



Pseudonymisation with Possible Re-Identification





(4) Pseudonymous Research Data Pool

- Same procedure as in (3),
 - But the secondary user builds a (disease specific) registry.
- Long term data accumulation needs special organisational and technical security measures.
- Quality management of data should precede pseudonymisation.
 - Yet another TTP service.
- »Model B« of the generic concept of the TMF.




(5) Central Clinical Data Base, Many Secondary Uses

- Data pool = central »clinical« data base.
 - Access for treating clinician (decentral).
 - No identity data, only PIDs.
 - Access by temporary tokens.
 - Implemented as (yet another) TTP service.
- No online access by secondary users.
 - Secondary users get exported data set (anonymised or pseudonymised).



TTPs for Central Clinical Data Base





Properties of Scenario (5)

• Advantages:

- Better support for long-term observation of patients with chronic diseases.
- Useful for the data producing clinician.
- Individual feedback of research results easy.
- Fits well into EHR architecture.

• Drawback:

- Sophisticated communication procedures.
- More TTPs and secret keys involved.

»Model A« of the generic concept of the TMF



Contents

- 1. EHR and Pseudonyms
- 2. 5 Scenarios for Secondary Use
- 3. Results
- 4. Discussion



Results I

- TMF models A and B [(5) and (4)] approved by the German Data Protection Commissioners
 - (Arbeitskreis Wissenschaft der Datenschutzbeauftragten des Bundes und der Länder)
- Scenario (2) in routine use since 2002 in a health care research project of the TMF.
- Scenario (5) implemented in a research network.
 - KN CED (Chronic Inflammatory Bowel Disease).
 - Further implementations in progress.



Results II

- Scenario (4) adapted by several research networks
 - Implementations in progress.
- TMF offers software tools for the TTP services.
- Corresponding policies, sample contracts, forms for patient's consent available from TMF (free for members).



Contents

- 1. EHR and Pseudonyms
- 2. 5 Scenarios for Secondary Use
- 3. Results
- 4. Discussion



Discussion I

- The TMF model architecture (variants A and B) provides ways for building central data pools for medical and health care research, that
 - conform to the German and European data protection rules,
 - respect the patients' rights,
 - and cover a wide range of situations.
- The pseudonymisation scenarios look complex, but once established, work transparently.



Discussion II

- The transfer to other applications in health care is possible and recommended.
 - We could and should build TTP services for secondary uses into the EHR architecture (suitably adapted from the TMF services).

